台灣醣聯生技醫藥股份有限公司
台灣醣聯生技醫藥股份有限公司（GlycoNex Incorporation）在台灣開發癌症藥物。研發管線利用醣類抗原及人類單株抗體技術，產品包括用於治療實體腫瘤的 GNX102 及 GNX201。亦開發用於骨質疏鬆及癌症骨轉移的 Denosumab 藥物。公司成立於 2001 年，總部位於台灣新北。
今日下跌 1.14%。該股 RSI(6) 為 46.3，處於中性區間，短線無明顯超買超賣訊號。股價跌破20日、60日、120日均線。短中期均線呈空頭排列，趨勢偏空。KD 指標中性（K=44.4）；MACD 柱狀體為正值，維持多方動能。 （自動產生 · 非投資建議）
| 日期 | 外資 | 投信 | 自營商 | 合計 |
|---|---|---|---|---|
| 09-29 | -6 | 0 | 0 | -6 |
| 09-24 | +1 | 0 | 0 | +1 |
| 09-23 | +1 | 0 | +2 | +1 |
| 09-22 | -14 | 0 | 0 | -14 |
| 09-21 | -2 | 0 | 0 | -2 |
| 09-18 | +29 | 0 | +1 | +29 |
| 09-17 | +26 | 0 | 0 | +25 |
| 09-16 | +6 | 0 | 0 | +6 |
| 09-15 | +12 | 0 | 0 | +12 |
| 09-14 | 0 | 0 | 0 | 0 |
| 09-11 | -17 | 0 | 0 | -17 |
| 09-10 | -12 | 0 | 0 | -12 |
| 09-09 | -13 | 0 | +6 | -13 |
| 09-08 | -5 | 0 | 0 | -5 |
| 09-07 | -9 | 0 | +2 | -9 |
| 09-04 | -50 | 0 | +2 | -50 |
| 09-03 | -6 | 0 | +2 | -6 |
| 09-02 | +27 | 0 | 0 | +27 |
| 09-01 | -15 | 0 | 0 | -15 |
| 08-31 | -2 | 0 | 0 | -2 |
| 08-28 | +12 | 0 | 0 | +12 |
| 08-27 | +52 | 0 | 0 | +52 |
| 08-26 | +6 | 0 | 0 | +6 |
| 08-25 | +6 | 0 | 0 | +6 |
| 08-24 | -2 | 0 | 0 | -2 |
| 08-21 | +2 | 0 | +2 | +3 |
| 08-20 | +8 | 0 | 0 | +8 |
| 08-19 | +11 | 0 | 0 | +10 |
| 08-18 | +17 | 0 | +2 | +17 |
| 08-17 | -13 | 0 | +2 | -13 |
| 08-14 | -4 | 0 | +2 | -3 |
| 08-13 | +4 | 0 | 0 | +4 |
| 08-12 | +8 | 0 | 0 | +8 |
| 08-11 | -1 | 0 | 0 | -1 |
| 08-10 | -21 | 0 | 0 | -21 |
| 08-07 | -28 | 0 | 0 | -28 |
| 08-06 | +3 | 0 | 0 | +3 |
| 08-05 | +6 | 0 | +2 | +7 |
| 08-04 | -26 | 0 | 0 | -26 |
| 08-03 | -28 | 0 | 0 | -28 |
| 07-31 | +20 | 0 | 0 | +20 |
| 07-30 | -7 | 0 | 0 | -7 |
| 07-29 | +91 | 0 | +6 | +91 |
| 07-28 | -8 | 0 | +2 | -8 |
| 07-27 | +18 | 0 | 0 | +18 |
| 07-24 | -10 | 0 | 0 | -10 |
| 07-23 | -25 | 0 | 0 | -25 |
| 07-22 | +22 | 0 | +2 | +22 |
| 07-21 | +9 | 0 | 0 | +9 |
| 07-20 | +11 | 0 | +2 | +12 |
| 07-17 | -46 | 0 | 0 | -47 |
| 07-16 | +1 | 0 | 0 | +1 |
| 07-15 | -5 | 0 | 0 | -5 |
| 07-14 | +33 | 0 | +2 | +33 |
| 07-13 | -46 | 0 | +2 | -46 |
| 07-09 | -32 | 0 | 0 | -32 |
| 07-08 | -36 | 0 | 0 | -36 |
| 07-07 | +117 | 0 | 0 | +117 |
| 07-06 | +200 | 0 | 0 | +200 |
| 07-03 | +119 | 0 | 0 | +119 |
| 07-02 | -7 | 0 | 0 | -7 |
| 07-01 | +19 | 0 | 0 | +19 |
| 06-30 | -44 | 0 | 0 | -44 |
| 06-29 | +89 | 0 | +2 | +89 |
| 06-26 | -110 | 0 | 0 | -110 |
| 06-25 | +34 | 0 | 0 | +34 |
| 06-24 | +50 | 0 | 0 | +50 |
| 06-23 | +57 | 0 | 0 | +57 |
| 06-22 | +40 | 0 | 0 | +40 |
| 06-18 | +16 | 0 | 0 | +16 |
| 06-17 | -38 | 0 | 0 | -39 |
| 06-16 | -13 | 0 | 0 | -13 |
| 06-15 | -91 | 0 | 0 | -91 |
| 06-12 | -191 | 0 | +6 | -191 |
| 06-11 | +4 | 0 | +7 | -133 |
| 06-10 | +8 | 0 | +2 | +9 |
| 06-09 | -59 | 0 | 0 | -60 |
| 06-08 | -79 | 0 | +2 | -78 |
| 06-05 | -14 | 0 | 0 | -14 |
| 06-04 | +24 | 0 | 0 | +24 |
| 06-03 | -32 | 0 | 0 | -32 |
| 06-02 | +38 | 0 | 0 | +38 |
| 06-01 | +9 | 0 | 0 | +9 |
| 05-29 | -162 | 0 | +4 | -162 |
| 月份 | 營收 | MoM% | YoY% |
|---|---|---|---|
| 2026/04 | 190 萬 | - | +185.7% |
| 2026/03 | 0 | -100.0% | - |
| 2026/02 | 1205 萬 | - | -11.2% |
| 2026/01 | 0 | -100.0% | - |
| 2025/12 | 440 萬 | - | +2979.7% |
| 2025/11 | 0 | - | -100.0% |
| 2025/10 | 0 | -100.0% | -100.0% |
| 2025/09 | 56 萬 | -82.9% | -74.1% |
| 2025/08 | 327 萬 | +11162.1% | +17089.5% |
| 2025/07 | 3 萬 | -38.3% | +52.6% |
| 2025/06 | 5 萬 | -99.7% | - |
| 2025/05 | 1532 萬 | - | +109350.0% |